Will PDUFA VI Fee Structure Changes Slow Revenue Growth?
User fee revenue expected to break $1bn threshold by FY 2020, but growth looks to be slower than last few years.
You may also be interested in...
Prescription drug user fee "receivables" nearly doubled in FY 2018, but the US FDA is not worried.
Office of New Drug's chief of staff will become Amgen's director of global regulatory policy and R&D.
Second consecutive year of record workload levels drive substantial increase in FDA's prescription drug user fee revenue target for fiscal year 2019.